A Phase 1, Open-Label, Positron Emission Tomography Study With [18F]MNI-794 to Determine Phosphodiesterase 2A Brain Enzyme Occupancy of TAK-915 After Single-Dose Oral Administration in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2016
At a glance
- Drugs TAK 915 (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- Sponsors Takeda
- 19 Jul 2016 Status changed from recruiting to completed.
- 18 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.
- 18 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.